A Study of Letrozole in the Treatment of Metastatic Breast Cancer in Combination With Chemotherapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective response rate (complete remission, partial remission,no change, progressive disease) by clinical palpation and radiologic imaging every 3 months until disease progression
Novartis
Study Chair
Novartis
United States: Food and Drug Administration
CFEM345ADE07
NCT00333047
July 2002
Name | Location |
---|